Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study
Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold...
Gespeichert in:
Veröffentlicht in: | European journal of medicinal chemistry 2018-01, Vol.144, p.635-650 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 650 |
---|---|
container_issue | |
container_start_page | 635 |
container_title | European journal of medicinal chemistry |
container_volume | 144 |
creator | Moussa, Ghandoura Alaaeddine, Rana Alaeddine, Lynn M. Nassra, Rasha Belal, Ahmed S.F. Ismail, Azza El-Yazbi, Ahmed F. Abdel-Ghany, Yasser S. Hazzaa, Aly |
description | Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products.
A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted]
•A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory. |
doi_str_mv | 10.1016/j.ejmech.2017.12.065 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1983255799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417310966</els_id><sourcerecordid>1983255799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCP0DIRw5N8EcSJxyQqlI-pAoucLYce7I7W8cusbPScuOf42oLR6TRzBze9x3NQ8grzmrOePd2X8N-BrurBeOq5qJmXfuEbLjq-kqKtnlKNkwIWbVCNmfkPKU9Y6ztGHtOzsQg-qHv1Yb8_hoP4Kn1aO_oHB1OaEYPNO8w_lwxmF_RY4gBEjWlQsYKw-TNPJsclyM1Wwg5vaMfIOE2XNJ0DHlX9nRJR4w-btEaT-Fg_GoyxlAiHHXR3mHY0pRXd3xBnk3GJ3j5OC_Ij483368_V7ffPn25vrqtrOxErgybul4NUio2GMvHHprWGGVVD1KObVO6ABjcCKyztpuMBNZPsjHOQWsUyAvy5pR7v5TPIGU9Y7LgvQkQ16T50BdsrRqGIm1OUrvElBaY9P2Cs1mOmjP9AF_v9Qm-foCvudAFfrG9frywjjO4f6a_tIvg_UkA5c8DwqKTRQgWHC5gs3YR_3_hD2UVm3M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983255799</pqid></control><display><type>article</type><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</creator><creatorcontrib>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</creatorcontrib><description>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products.
A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted]
•A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.12.065</identifier><identifier>PMID: 29289887</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis ; Anti-Inflammatory Agents, Non-Steroidal - chemistry ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Arachidonate 15-Lipoxygenase - metabolism ; Cell Differentiation - drug effects ; Click Chemistry ; Click reaction ; Cyclooxygenase 1 - metabolism ; Cyclooxygenase 1/cyclooxygenase 2 ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase Inhibitors - chemical synthesis ; Cyclooxygenase Inhibitors - chemistry ; Cyclooxygenase Inhibitors - pharmacology ; Docking ; Dose-Response Relationship, Drug ; Drug Design ; Drug-likeness ; Female ; Humans ; Lipooxygenase ; Lipoxygenase Inhibitors - chemical synthesis ; Lipoxygenase Inhibitors - chemistry ; Lipoxygenase Inhibitors - pharmacology ; Macrophages - drug effects ; Molecular Docking Simulation ; Molecular Structure ; Monocyte/macrophage ; Quinazolinones - chemical synthesis ; Quinazolinones - chemistry ; Quinazolinones - pharmacology ; Rats ; Rats, Wistar ; Structure-Activity Relationship ; Sulfhydryl Compounds - chemical synthesis ; Sulfhydryl Compounds - chemistry ; Sulfhydryl Compounds - pharmacology ; Thioquinazolinone ; Tumor Cells, Cultured</subject><ispartof>European journal of medicinal chemistry, 2018-01, Vol.144, p.635-650</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</citedby><cites>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523417310966$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29289887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moussa, Ghandoura</creatorcontrib><creatorcontrib>Alaaeddine, Rana</creatorcontrib><creatorcontrib>Alaeddine, Lynn M.</creatorcontrib><creatorcontrib>Nassra, Rasha</creatorcontrib><creatorcontrib>Belal, Ahmed S.F.</creatorcontrib><creatorcontrib>Ismail, Azza</creatorcontrib><creatorcontrib>El-Yazbi, Ahmed F.</creatorcontrib><creatorcontrib>Abdel-Ghany, Yasser S.</creatorcontrib><creatorcontrib>Hazzaa, Aly</creatorcontrib><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products.
A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted]
•A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemistry</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Arachidonate 15-Lipoxygenase - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Click Chemistry</subject><subject>Click reaction</subject><subject>Cyclooxygenase 1 - metabolism</subject><subject>Cyclooxygenase 1/cyclooxygenase 2</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase Inhibitors - chemical synthesis</subject><subject>Cyclooxygenase Inhibitors - chemistry</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Docking</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Drug-likeness</subject><subject>Female</subject><subject>Humans</subject><subject>Lipooxygenase</subject><subject>Lipoxygenase Inhibitors - chemical synthesis</subject><subject>Lipoxygenase Inhibitors - chemistry</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Macrophages - drug effects</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>Monocyte/macrophage</subject><subject>Quinazolinones - chemical synthesis</subject><subject>Quinazolinones - chemistry</subject><subject>Quinazolinones - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Structure-Activity Relationship</subject><subject>Sulfhydryl Compounds - chemical synthesis</subject><subject>Sulfhydryl Compounds - chemistry</subject><subject>Sulfhydryl Compounds - pharmacology</subject><subject>Thioquinazolinone</subject><subject>Tumor Cells, Cultured</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EotvCP0DIRw5N8EcSJxyQqlI-pAoucLYce7I7W8cusbPScuOf42oLR6TRzBze9x3NQ8grzmrOePd2X8N-BrurBeOq5qJmXfuEbLjq-kqKtnlKNkwIWbVCNmfkPKU9Y6ztGHtOzsQg-qHv1Yb8_hoP4Kn1aO_oHB1OaEYPNO8w_lwxmF_RY4gBEjWlQsYKw-TNPJsclyM1Wwg5vaMfIOE2XNJ0DHlX9nRJR4w-btEaT-Fg_GoyxlAiHHXR3mHY0pRXd3xBnk3GJ3j5OC_Ij483368_V7ffPn25vrqtrOxErgybul4NUio2GMvHHprWGGVVD1KObVO6ABjcCKyztpuMBNZPsjHOQWsUyAvy5pR7v5TPIGU9Y7LgvQkQ16T50BdsrRqGIm1OUrvElBaY9P2Cs1mOmjP9AF_v9Qm-foCvudAFfrG9frywjjO4f6a_tIvg_UkA5c8DwqKTRQgWHC5gs3YR_3_hD2UVm3M</recordid><startdate>20180120</startdate><enddate>20180120</enddate><creator>Moussa, Ghandoura</creator><creator>Alaaeddine, Rana</creator><creator>Alaeddine, Lynn M.</creator><creator>Nassra, Rasha</creator><creator>Belal, Ahmed S.F.</creator><creator>Ismail, Azza</creator><creator>El-Yazbi, Ahmed F.</creator><creator>Abdel-Ghany, Yasser S.</creator><creator>Hazzaa, Aly</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180120</creationdate><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><author>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemistry</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Arachidonate 15-Lipoxygenase - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Click Chemistry</topic><topic>Click reaction</topic><topic>Cyclooxygenase 1 - metabolism</topic><topic>Cyclooxygenase 1/cyclooxygenase 2</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase Inhibitors - chemical synthesis</topic><topic>Cyclooxygenase Inhibitors - chemistry</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Docking</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Drug-likeness</topic><topic>Female</topic><topic>Humans</topic><topic>Lipooxygenase</topic><topic>Lipoxygenase Inhibitors - chemical synthesis</topic><topic>Lipoxygenase Inhibitors - chemistry</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Macrophages - drug effects</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>Monocyte/macrophage</topic><topic>Quinazolinones - chemical synthesis</topic><topic>Quinazolinones - chemistry</topic><topic>Quinazolinones - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Structure-Activity Relationship</topic><topic>Sulfhydryl Compounds - chemical synthesis</topic><topic>Sulfhydryl Compounds - chemistry</topic><topic>Sulfhydryl Compounds - pharmacology</topic><topic>Thioquinazolinone</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moussa, Ghandoura</creatorcontrib><creatorcontrib>Alaaeddine, Rana</creatorcontrib><creatorcontrib>Alaeddine, Lynn M.</creatorcontrib><creatorcontrib>Nassra, Rasha</creatorcontrib><creatorcontrib>Belal, Ahmed S.F.</creatorcontrib><creatorcontrib>Ismail, Azza</creatorcontrib><creatorcontrib>El-Yazbi, Ahmed F.</creatorcontrib><creatorcontrib>Abdel-Ghany, Yasser S.</creatorcontrib><creatorcontrib>Hazzaa, Aly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moussa, Ghandoura</au><au>Alaaeddine, Rana</au><au>Alaeddine, Lynn M.</au><au>Nassra, Rasha</au><au>Belal, Ahmed S.F.</au><au>Ismail, Azza</au><au>El-Yazbi, Ahmed F.</au><au>Abdel-Ghany, Yasser S.</au><au>Hazzaa, Aly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2018-01-20</date><risdate>2018</risdate><volume>144</volume><spage>635</spage><epage>650</epage><pages>635-650</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products.
A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted]
•A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>29289887</pmid><doi>10.1016/j.ejmech.2017.12.065</doi><tpages>16</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0223-5234 |
ispartof | European journal of medicinal chemistry, 2018-01, Vol.144, p.635-650 |
issn | 0223-5234 1768-3254 |
language | eng |
recordid | cdi_proquest_miscellaneous_1983255799 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis Anti-Inflammatory Agents, Non-Steroidal - chemistry Anti-Inflammatory Agents, Non-Steroidal - pharmacology Arachidonate 15-Lipoxygenase - metabolism Cell Differentiation - drug effects Click Chemistry Click reaction Cyclooxygenase 1 - metabolism Cyclooxygenase 1/cyclooxygenase 2 Cyclooxygenase 2 - metabolism Cyclooxygenase Inhibitors - chemical synthesis Cyclooxygenase Inhibitors - chemistry Cyclooxygenase Inhibitors - pharmacology Docking Dose-Response Relationship, Drug Drug Design Drug-likeness Female Humans Lipooxygenase Lipoxygenase Inhibitors - chemical synthesis Lipoxygenase Inhibitors - chemistry Lipoxygenase Inhibitors - pharmacology Macrophages - drug effects Molecular Docking Simulation Molecular Structure Monocyte/macrophage Quinazolinones - chemical synthesis Quinazolinones - chemistry Quinazolinones - pharmacology Rats Rats, Wistar Structure-Activity Relationship Sulfhydryl Compounds - chemical synthesis Sulfhydryl Compounds - chemistry Sulfhydryl Compounds - pharmacology Thioquinazolinone Tumor Cells, Cultured |
title | Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A34%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20click%20modifiable%20thioquinazolinones%20as%20anti-inflammatory%20agents:%20Design,%20synthesis,%20biological%20evaluation%20and%20docking%20study&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Moussa,%20Ghandoura&rft.date=2018-01-20&rft.volume=144&rft.spage=635&rft.epage=650&rft.pages=635-650&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.12.065&rft_dat=%3Cproquest_cross%3E1983255799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983255799&rft_id=info:pmid/29289887&rft_els_id=S0223523417310966&rfr_iscdi=true |